Skip to main content

Market Overview

Shkreli: I'd Short Immunomedics On The Bounce

Shkreli: I'd Short Immunomedics On The Bounce

Immunomedics, Inc. (NASDAQ: IMMU) shares are on a strong upswing, hitting a two-year high, on roughly 27-times their average volume.

The Catalyst

The biopharmaceutical company specializing in antibody-based therapeutics announced that it has inked an exclusive global licensing agreement with Seattle Genetics, Inc. (NASDAQ: SGEN) for its Sacituzumab Govitecan, code named IMMU-32. The treatment candidate has the potential for being the first ever approved therapy specifically for advanced metastatic triple-negative breast cancer. Immunomedics stands to gain potential payments of up to about $2 billion, plus royalties.

Separately, the company announced postponement of its 2016 Annual Meeting of Stockholders previously scheduled for February 16. The meeting has been postponed to March 3 at 10:00 a.m. ET.

Payment Breakup

  • Upfront cash payment: $250 million.
  • Among other milestone payments, an additional $50 million or negotiated economic splits relating to rights outside the United States, Canada and the EU.
  • Milestone payments of up to $1.7 billion.
  • Seattle Genetics to make up to $57 million equity investment for up to 9.9 percent stake in Immunomedics through purchase of 3 million common stock representing a 2.8 percent stake and a three-year warrant.

Other Terms

The agreement provides for Seattle Genetics developing manufacturing and commercializing IMMU-132 in multiple locations, while Immunomedics would retain rights to co-promote in the United States.

Shkreli Recommends Shorting

In a Facebook Inc (NASDAQ: FB) post, Martin Shkreli said he would short Immunomedics on the bounce. "I can't believe they got $250 million for this irinotecan prodrug. The world has moved on from old chemo mechanisms to targeted/IO. That'll be the last $250 they get," he said in the post.

At Time Of Writing

  • Immunomedics was skyrocketing 20.42 percent to $5.17.
  • Seattle Genetics was slipping 3.26 percent to $60.76.

Latest Ratings for IMMU

Sep 2020JefferiesDowngradesBuyHold
Sep 2020Wells FargoDowngradesOverweightEqual-Weight
Sep 2020HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for IMMU
View the Latest Analyst Ratings


Related Articles (IMMU)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Short Ideas Health Care Analyst Ratings Movers Media Best of Benzinga

Latest Ratings

RCI.BCanaccord GenuityMaintains71.0
AIFCanaccord GenuityReiterates70.0
SBNYRaymond JamesMaintains300.0
XMRaymond JamesMaintains45.0
NTGRRaymond JamesMaintains48.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at